Search Results (8)

Nanoparticles have emerged as a prominent area of research in recent times, and silver nanoparticles (AgNPs) synthesized via phyco-technology have gained significant attention due to their potential therapeutic applications. Nodularia haraviana, a unique and lesser-explored cyanobacterial strain, holds substantial promise as a novel candidate for synthesizing nanoparticles. This noticeable research gap underscores the novelty and untapped potential of Nodularia haraviana in applied nanotechnology. A range of analytical techniques, including UV-vis spectral analysis, dynamic light scattering spectroscopy, scanning electron microscopy, Fourier transform infrared spectroscopy, and X-ray powder diffraction, were used to investigate and characterize the AgNPs. Successful synthesis of AgNPs was confirmed through UV-visible spectroscopy, which showed a surface plasmon resonance peak at 428 nm. The crystalline size of AgNPs was 24.1 nm. Dynamic light scattering analysis revealed that silver oxide nanoparticles had 179.3 nm diameters and a negative surface charge of −18 mV. Comprehensive in vitro pharmacogenetic properties revealed that AgNPs have significant therapeutic potential. The antimicrobial properties of AgNPs were evaluated by determining the minimum inhibitory concentration against various microbial strains. Dose-dependent cytotoxicity assays were performed on Leishmanial promastigotes (IC₅₀: 18.71 μgmL⁻¹), amastigotes (IC50: 38.6 μgmL⁻¹), and brine shrimps (IC₅₀: 134.1 μg mL⁻¹) using various concentrations of AgNPs. The findings of this study revealed that AgNPs had significant antioxidant results (DPPH: 57.5%, TRP: 55.4%, TAC: 61%) and enzyme inhibition potential against protein kinase (ZOI: 17.11 mm) and alpha-amylase (25.3%). Furthermore, biocompatibility tests were performed against macrophages (IC₅₀: >395 μg mL⁻¹) and human RBCs (IC₅₀: 2124 μg mL⁻¹). This study showed that phyco-synthesized AgNPs were less toxic and could be used in multiple biological applications, including drug design and in the pharmaceutical and biomedical industries. This study offers valuable insights and paves the way for further advancements in AgNPs research. Full article

Metallic nanoparticles have received a significant amount of reflection over a period of time, attributed to their electronic, specific surface area, and surface atom properties. The biogenic synthesis of iron oxide nanoparticles (FeONPs) is demonstrated in this study. The green synthesis of metallic nanoparticles (NPs) is acquiring considerable attention due to its environmental and economic superiorities over other methods. Leptolyngbya sp. L-2 extract was employed as a reducing agent, and iron chloride hexahydrate (FeCl₃·6H₂O) was used as a substrate for the biogenic synthesis of FeONPs. Different spectral methods were used for the characterization of the biosynthesized FeONPs, ultraviolet-visible (UV-Vis) spectroscopy gave a surface plasmon resonance (SPR) peak of FeONPs at 300 nm; Fourier transform infrared (FTIR) spectral analysis was conducted to identify the functional groups responsible for both the stability and synthesis of FeONPs. The morphology of the FeONPs was investigated using scanning electron microscopy (SEM), which shows a nearly spherical shape, and an X-ray diffraction (XRD) study demonstrated their crystalline nature with a calculated crystallinity size of 23 nm. The zeta potential (ZP) and dynamic light scattering (DLS) measurements of FeONPs revealed values of −8.50 mV, suggesting appropriate physical stability. Comprehensive in-vitro pharmacogenetic properties revealed that FeONPs have significant therapeutic potential. FeONPs have been reported to have potential antibacterial and antifungal properties. Dose-dependent cytotoxic activity was shown against Leishmania tropica promastigotes (IC50: 10.73 µg/mL) and amastigotes (IC50: 16.98 µg/mL) using various concentrations of FeONPs. The cytotoxic potential was also investigated using brine shrimps, and their IC50 value was determined to be 34.19 µg/mL. FeONPs showed significant antioxidant results (DPPH: 54.7%, TRP: 49.2%, TAC: 44.5%), protein kinase (IC50: 96.23 µg/mL), and alpha amylase (IC50: 3745 µg/mL). The biosafety of FeONPs was validated by biocompatibility tests using macrophages (IC50: 918.1 µg/mL) and red blood cells (IC50: 2921 µg/mL). In conclusion, biogenic FeONPs have shown potential biomedical properties and should be the focus of more studies to increase their nano-pharmacological significance for biological applications. Full article

Zinc oxide nanoparticles (ZnONPs) are the top candidate in the field of biological applications because of their high surface area and excellent catalytic activities. In the present study, the cyanobacteria-mediated biosynthesis of zinc oxide NPs using Nostoc sp. extract as a stabilizing, chelating, and reducing agent is reported. ZnONPs were biologically synthesized using an eco-friendly and simple technique with a minimal reaction time and calcination temperature. Various methods, including X-ray diffraction (XRD), ultraviolet spectroscopy (UV), Fourier transform infrared (FTIR), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX) were used to characterize the biosynthesized zinc oxide NPs. XRD analysis depicted the crystalline form of zinc oxide NPs, and the Scherrer equation determined a mean crystalline size of ~28.21 nm. The SEM results reveal the spherical shape of the biosynthesized nanoparticles. Various functional groups were involved in the capping and stabilization of the zinc oxide NPs, which were confirmed by FTIR analysis. The zinc oxide NPs showed strong UV-vis absorption at 340 nm. Multiple in vitro biological applications showed significant therapeutic potential for zinc oxide NPs. Potential antimicrobial assays were reported for zinc oxide NPs via the disc-diffusion method and food poisoning method, respectively. All other activities mentioned below are described with the concentration and IC50 values. Biocompatibility with human erythrocytes and macrophages (IC50: 433 µg/mL, IC50 > 323 µg/mL) and cytotoxic properties using brine shrimps (IC50: 11.15 µg/mL) and Leishmania tropics (Amastigotes IC50: 43.14 µg mL⁻¹ and Promastigotes IC50: 14.02 µg mL⁻¹) were determined. Enzyme inhibition assays (protein kinase and alpha amylase) were performed and showed strong potential. Free radical scavenging tests showed strong antioxidant capacities. These results indicate that zinc oxide NPs synthesized by Nostoc sp. have strong biological applications and are promising candidates for clinical development. Full article

Trypanosoma cruzi is the etiologic agent of Chagas disease, a parasitic disease of great medical importance on the American continent. Trypomastigote infection’s initial step in a mammalian host is vital for the parasite’s life cycle. A trypomastigote’s surface presents many molecules, some of which have been proposed to be involved in the infection process, including a glycoprotein family called mucin-associated surface proteins (MASPs). This work describes a 49-kDa molecule (MASP49) that belongs to this family and is expressed mainly on the surfaces of amastigotes and trypomastigotes but can be found in extracts and the membrane-enriched fractions of epimastigotes. This protein is partially GPI-anchored to the surface and has a role during the internalization process, since its blockade with specific antibodies decreases parasite entry into Vero cells by 62%. This work shows that MASP49 binds to peritoneal macrophages and rat cardiomyocytes, undergoes glycosylation via galactose N-acetylgalactosamine, and can attach to the macrophage murine C-type lectin receptor (mMGL). These results suggest that MASP49 can be considered a virulence factor in T. cruzi, and a better understanding of its role in the infection process is necessary. Full article

Leishmaniasis, a neglected tropical parasitic disease (NTPD), is caused by various Leishmania species. It transmits through the bites of the sandfly. The parasite is evolving resistance to commonly prescribed antileishmanial drugs; thus, there is an urgent need to discover novel antileishmanial drugs to combat drug-resistant leishmaniasis. Thymoquinone (2-isopropyl-5-methyl-1,4-benzoquinone; TQ), a primary pharmacologically active ingredient of Nigella sativa (black seed) essential oil, has been reported to possess significant antiparasitic activity. Therefore, the present study was designed to investigate the in vitro and in silico antileishmanial activity of TQ against various infectious stages of Leishmania major (L. major), i.e., promastigotes and amastigotes, and its cytotoxicity against mice macrophages. In silico molecular dockings of TQ were also performed with multiple selected target proteins of L. major, and the most preferred antileishmanial drug target protein was subjected to in silico molecular dynamics (MD) simulation. The in vitro antileishmanial activity of TQ revealed that the half-maximal effective concentration (EC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) values for promastigotes are 2.62 ± 0.12 μM, 29.54 ± 0.07 μM, and 11.27, while for the amastigotes, they are 17.52 ± 0.15 μM, 29.54 ± 0.07 μM, and 1.69, respectively. The molecular docking studies revealed that squalene monooxygenase is the most preferred antileishmanial drug target protein for TQ, whereas triosephosphate isomerase is the least preferred. The MD simulation revealed that TQ remained stable in the binding pocket throughout the simulation. Additionally, the binding energy calculations using Molecular Mechanics Generalized-Born Surface Area (MMGBSA) indicated that TQ is a moderate binder. Thus, the current study shows that TQ is a promising antileishmanial drug candidate that could be used to treat existing drug-resistant leishmaniasis. Full article

Leishmaniasis, a Neglected Tropical Parasitic Disease (NTPD), is induced by several Leishmania species and is disseminated through sandfly (Lutzomyia longipalpis) bites. The parasite has developed resistance to currently prescribed antileishmanial drugs, and it has become pertinent to the search for new antileishmanial agents. The current study aimed to investigate the in vitro and in silico antileishmanial activity of two newly sourced actinomycins, X₂ and D, produced by the novel Streptomyces smyrnaeus strain UKAQ_23. The antileishmanial activity conducted on promastigotes and amastigotes of Leishmania major showed actinomycin X₂ having half-maximal effective concentrations (EC₅₀), at 2.10 ± 0.10 μg/mL and 0.10 ± 0.0 μg/mL, and selectivity index (SI) values of 0.048 and 1, respectively, while the actinomycin D exhibited EC₅₀ at 1.90 ± 0.10 μg/mL and 0.10 ± 0.0 μg/mL, and SI values of 0.052 and 1. The molecular docking studies demonstrated squalene synthase as the most favorable antileishmanial target protein for both the actinomycins X₂ and D, while the xanthine phosphoribosyltransferase was the least favorable target protein. The molecular dynamics simulations confirmed that both the actinomycins remained stable in the binding pocket during the simulations. Furthermore, the MMPBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) binding energy calculations established that the actinomycin X₂ is a better binder than the actinomycin D. In conclusion, both actinomycins X₂ and D from Streptomyces smyrnaeus strain UKAQ_23 are promising antileishmanial drug candidates and have strong potential to be used for treating the currently drug-resistant leishmaniasis. Full article

While numerous genomes of Leishmania spp. have been sequenced and analyzed, an understanding of the evolutionary history of these organisms remains limited due to the unavailability of the sequence data for their closest known relatives, Endotrypanum and Porcisia spp., infecting sloths and porcupines. We have sequenced and analyzed genomes of three members of this clade in order to fill this gap. Their comparative analyses revealed only minute differences from Leishmaniamajor genome in terms of metabolic capacities. We also documented that the number of genes under positive selection on the Endotrypanum/Porcisia branch is rather small, with the flagellum-related group of genes being over-represented. Most significantly, the analysis of gene family evolution revealed a substantially reduced repertoire of surface proteins, such as amastins and biopterin transporters BT1 in the Endotrypanum/Porcisia species when compared to amastigote-dwelling Leishmania. This reduction was especially pronounced for δ-amastins, a subfamily of cell surface proteins crucial in the propagation of Leishmania amastigotes inside vertebrate macrophages and, apparently, dispensable for Endotrypanum/Porcisia, which do not infect such cells. Full article

Due to the increasing amount of people afflicted worldwide with Chagas disease and an increasing prevalence in the United States, there is a greater need to develop a safe and effective vaccine for this neglected disease. Adenovirus serotype 5 (Ad5) is the most common adenovirus vector used for gene therapy and vaccine approaches, but its efficacy is limited by preexisting vector immunity in humans resulting from natural infections. Therefore, we have employed rare serotype adenovirus 48 (Ad48) as an alternative choice for adenovirus/Chagas vaccine therapy. In this study, we modified Ad5 and Ad48 vectors to contain T. cruzi’s amastigote surface protein 2 (ASP-2) in the adenoviral early gene. We also modified Ad5 and Ad48 vectors to utilize the “Antigen Capsid-Incorporation” strategy by adding T. cruzi epitopes to protein IX (pIX). Mice that were immunized with the modified vectors were able to elicit T. cruzi-specific humoral and cellular responses. This study indicates that Ad48-modified vectors function comparable to or even premium to Ad5-modified vectors. This study provides novel data demonstrating that Ad48 can be used as a potential adenovirus vaccine vector against Chagas disease. Full article